...
首页> 外文期刊>Behavioural Brain Research: An International Journal >Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors
【24h】

Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors

机译:胍丁胺减轻小鼠利血平诱导的口腔运动障碍:氧化应激,一氧化氮和谷氨酸NMDA受体的作用

获取原文
获取原文并翻译 | 示例

摘要

Dyskinesia consists in a series of trunk, limbs and orofacial involuntary movements that can be observed following long-term pharmacological treatment in some psychotic and neurological disorders such as schizophrenia and Parkinson's disease, respectively. Agmatine is an endogenous arginine metabolite that emerges as neuromodulator and a promising agent to manage diverse central nervous system disorders by modulating nitric oxide (NO) pathway, glutamate NMDA receptors and oxidative stress. Herein, we investigated the effects of a single intraperitoneal (i.p.) administration of different agmatine doses (10, 30 or 100 mg/kg) against the orofacial dyskinesia induced by reserpine (1 mg/kg, s.c.) in mice by measuring the vacuous chewing movements and tongue protusion frequencies, and the duration of facial twitching. The results showed an orofacial antidyskinetic effect of agmatine (30 mg/kg, i.p.) or the combined administration of sub-effective doses of agmatine (10 mg/kg, i.p.) with the NMDA receptor antagonists amantadine (1 mg/kg, i.p.) and MK801 (0.01 mg/kg, i.p.) or the neuronal nitric oxide synthase (NOS) inhibitor 7-nitroindazole (7-NI; 0.1 mg/kg, i.p.). Reserpine-treated mice displayed locomotor activity deficits in the open field and agmatine had no effect on this response. Reserpine increased nitrite and nitrate levels in cerebral cortex, but agmatine did not reverse it. Remarkably, agmatine reversed the decrease of dopamine and non-protein thiols (NPSH) levels caused by reserpine in the striatum. However, no changes were observed in striatal immunocontent of proteins related to the dopaminergic system including tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter type 2, pDARPP-32[Thr75], dopamine D-1 and D-2 receptors. These results indicate that the blockade of NO pathway, NMDAR and oxidative stress are possible mechanisms associated with the protective effects of agmatine against the orofacial dyskinesia induced by reserpine in mice. (C) 2016 Elsevier B.V. All rights reserved.
机译:运动障碍包括一系列躯干,四肢和口面部非自愿运动,分别在某些精神病和神经病(例如精神分裂症和帕金森氏病)中进行长期药物治疗后即可观察到。胍丁胺是一种内源性精氨酸代谢产物,它作为神经调节剂出现,并且是通过调节一氧化氮(NO)途径,谷氨酸NMDA受体和氧化应激来管理各种中枢神经系统疾病的有前途的药物。本文中,我们通过测量空腹咀嚼来研究小鼠腹膜内(ip)施用不同剂量的胍丁胺(10、30或100 mg / kg)对利血平(1 mg / kg,sc)引起的口面运动障碍的影响动作和舌头突出的频率,以及面部抽搐的持续时间。结果显示胍丁胺(30 mg / kg,腹膜内)的口部抗动力学作用或亚有效剂量的胍丁胺(10 mg / kg,腹膜内)与NMDA受体拮抗剂金刚烷胺(1 mg / kg,腹膜内)联合给药MK801(0.01 mg / kg,ip)或神经元一氧化氮合酶(NOS)抑制剂7-硝基吲唑(7-NI; 0.1 mg / kg,ip)。利血平治疗的小鼠在旷野中显示出运动活动不足,而胍丁胺对此反应没有影响。利血平可增加大脑皮层的亚硝酸盐和硝酸盐含量,但胍丁胺不能逆转。值得注意的是,胍丁胺逆转了纹状体中利血平引起的多巴胺和非蛋白硫醇(NPSH)水平的降低。然而,未观察到与多巴胺能系统有关的蛋白质的纹状体免疫含量发生变化,包括酪氨酸羟化酶,多巴胺转运蛋白,2型囊泡单胺转运蛋白,pDARPP-32 [Thr75],多巴胺D-1和D-2受体。这些结果表明,NO途径的阻断,NMDAR和氧化应激是可能的机制,其与胍丁胺对利血平诱导的小鼠口面部运动障碍的保护作用有关。 (C)2016 Elsevier B.V.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号